In this webcast, learn the latest clinical evidence for incorporating TROP-2 targeted antibody drug conjugates into the care of patients with advanced NSCLC.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/trop2-adcs-for-nsclc/18834-28820
- Start Date: 2024-04-10 05:00:00
- End Date: 2024-04-10 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- Commercial Support: Source: Gilead Sciences, Inc. - Amount: 164850.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest